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frequency of SLCO1B3 (rs60140950) 
showed the opposite result 
(appendix). Meanwhile, we also col-
lected 432 SARS-CoV-2 samples 
from China and 2754 SARS-CoV-2 
samples from the USA using an online 
database.7 The frequency of poten-
tial functional variations such as 
p.P4715L (c.14144C>T) in polyprotein 
1ab, which is the target of remdesivir, 
were largely different in the genomes 
from the USA (63·0%) and China 
(11·2%). These variations could 
generate the efficacy discrepancy of 
remdesivir among these clinical trials.
Similar to remdesivir, ethnic diversity 
was also found in pharmacogenes 
related to other drugs, such as 
chloroquine, in COVID-19 treatment. 
In summary, pharmacogenomic 
studies for COVID-19 therapy seem to 
be needed urgently.
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The Panel on Antiretroviral Guidelines 
for Adults and Adolescents with HIV 
and the American Association for the 
Study of Liver Diseases guidelines 
for hepatitis C virus treatment 
suggest that combination therapy for 
severe acute respiratory syn drome 
coronavirus 2 infection will outperform 
single drugs. Yeming Wang and 
colleagues1 reported that the hazard 
of 28-day clinical improvement for 
158 patients with severe COVID-19 
randomly assigned to remdesivir 
was 1·2 times (95% CI 0·9 to 1·8) the 
hazard of patients randomly assigned 
to placebo, but the 28-day mortality 
in both these groups was similar. 
Relatedly, Cao and colleagues2 reported 
that the hazard of 28-day clinical 
improvement for 99 patients with 
severe COVID-19 randomly assigned 
to lopinavir-ritonavir was 1·3 times 
(95% CI 1·0 to 1·8) the hazard among 
100 patients randomly assigned 
to standard care, and the 28-day 
mortality was reduced by 6% (95% CI 
–17 to 6). Nearly 20% of patients in the 
Wang and colleagues1 trial were also 
receiving lopinavir-ritonavir, but their 
results are not stratified by lopinavir-
ritonavir status. Reporting estimates 
stratified by concomitant lopinavir-
ritonavir use would help guide the 
design of future (factorial) trials that 
investigate the joint effects of these 
two therapies, even if imprecise. Also, 
reporting the proportion of patients 
clinically improved at 28 days is more 
interpretable than the hazard ratio.
Additionally, Wang and colleagues1 
report that the effect of remdesivir 
on clinical improvement appeared 
stronger among patients who started 
treatment within 10 days of symptom 
onset than among those who started 
later. Cao and colleagues2 reported 
similar strengthening of the lopinavir-
ritonavir treatment effect among 
patients who started treatment 
within 14 days of symptom onset. As 
in HIV,3 timing of treatment initiation 
for COVID-19 appears to be of crucial 
importance in the design of future 
research.
In a Chinese clinical trial by Yeming Wang 
and colleagues,1 remdesivird did not 
show significant benefits for patients 
with severe COVID-19. Shortly after their 
study was published, remdesivir was 
authorised in the USA by the US Food 
& Drug Administration2 and approved 
in Japan3 for patients with severe 
COVID-19 on the basis of preliminary 
phase 3 trial results.4 We find it puzzling 
that the discrepancy of results between 
China and the USA is merely justified by 
different study designs.
Genetic factors can influence drugs’ 
efficacy and toxicity. Therefore, 
it is reasonable to seek answers 
from the genetic backgrounds of 
patients with COVID-19 and of 
severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) in China 
and the USA. From the GnomAD 
database, we collected: 9977 genomes 
from east Asia that represented 
Chinese people; and 64 603 genomes 
from Europeans, 17 720 from Latinx, 
and 12 487 from African Americans, 
which represented the three majority 
ethnicities in the USA.5 Genetic diversity 
was found in seven pharmacogenes 
that mainly related to pharmacokinetics 
and pharmacodynamics of remdesivir.6 
Notably, the mutation frequency 
of CYP2D6 (rs1065852) in east Asia 
(57·7%) was much greater than 
that of the American ethnicities 
(12·3–21·7%), whereas the mutation 
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